glp-1 increased heart rate Effects of Glucagon-Like Peptide 1 Receptor Agonist Initiation in Patients With Failure With Reduced Ejection Fraction and Implantable Cardiac Devices TrimRX | Cardiovascular Risks of

The closest performing GLP-1 medicine in terms of average weight loss is Novo Nordisks CagriSema, an Amylin/GLP-1 dual agonist, which had an average weight loss of 22.7% after 68 weeks in Phase 3 trials

The bigger issue is sugary drinks, desserts, and refined-carb foods that cause blood sugar spikes and provide calories without satiety

It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously activates three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors

Brand drugs to be covered at a lower tier when there is not a brand drug alternative covered at that tier